Highlights • Segmental ureterectomy was feasible for selected ureteral cancer patients. • Segmental ureterectomy faced a considerable risk of local recurrence and intravesical recurrence. • G3 and lymphatic vascular infiltration…
Highlights • A study in patients with unresectable or metastatic urothelial carcinoma (mUC). • Half of patients received cisplatin-based regimens as first-line therapy. • After 2017, 58.2% of patients received…
Highlights • Bempegaldesleukin is a pegylated interleukin-2 cytokine. • This phase 2 study was conducted in patients previously untreated advanced or metastatic urothelial carcinoma and low PD-L1 expression. • The…
Abstract Background For patients with metastatic bladder cancer (mBC) palliative chemotherapy is one of the main treatment options. Real-world insights into outcomes are available, but a comprehensive overview of specific…
Highlights • Critical care therapy represents a 5- to 6-fold multiple of in-hospital mortality rate. Moreover, critical care therapy very closely reflects in-hospital mortality rate changes that occurred over time…
Highlights • The standard prostate biopsy method results in overdiagnosis and overtreatment. • ips-SB+TB can be an alternative for detecting prostate cancer (PCa). • Ips-SB+TB has comparable efficiency in detecting…
Abstract Background Burnout is a significant issue among GU oncologists, driven by increasing workloads and the emotional demands of patient care. This study aims to identify the prevalence, risk factors,…
Highlights • Patients undergoing cystectomy have significant emotional and mental health needs. • Providers should proactively address the mental health needs of these patients. • Mental health specialists should be…
Highlights • This is the first systematic review and meta-analysis, including randomized controlled trials, to investigate the oncological outcomes of adjuvant therapy after radical adrenalectomy in patients with adrenocortical carcinoma….
Highlights • Development of novel therapies is needed for patients with high-risk bladder cancer. • TAR-200 is a gemcitabine intravesical releasing system designed for bladder cancer. • TAR-200 was well…
